Recent Articles

October 31, 2014 11:22 am
Cynthia Fox, Science Editor
The most potent stem cells are coming to patients after helping blind (and nearly blind) mice see for years. Read more...                                                                                
October 29, 2014 12:20 pm
Neil Canavan
Since cancer immunotherapy was declared the Breakthrough of the Year in 2013 by Science magazine the field has been on fire, and its relatively few experts have been on the run– explaining the nascent technology and related data to oncologists at venues from the April meeting of AACR in San Diego, to the June meeting of ASCO in Chicago, to the September meeting of ESMO in Madrid.  Read more...
October 27, 2014 4:01 pm
Chandreyee Das, Ph.D., Senior Technical Writer, Protein Detection, EMD Millipore
Many biological samples in the course of drug development research are rich in lipid content, such as adipose tissue homogenates, brain and liver tissue extracts, lipemic samples and breast milk. Read more...
October 20, 2014 4:08 pm
Cynthia Fox, Science Editor
As San Diego’s ViaCyte was in the midst of launching the first FDA-approved embryonic stem (ES) cell clinical trial for diabetes last week, Boston’s Harvard University reported that beta cells from ES cells “cured” diabetic mouse-models. Read more...
October 17, 2014 9:57 am
Daniel L. Alkon, M.D.,Chief Scientific Officer, Neurotrope Inc. and Toyota Chair in Neurodegenerative Disease, Scientific Director and Professor, Blanchette Rockefeller Neurosciences Institute
Alzheimer's disease (AD) afflicts more than 5 million people in the U.S. and 40 million worldwide, generating annual healthcare costs that exceed $200 billion in the U.S. and $600 billion globally. By 2050, AD is expected to strike more than 115 million patients per year, according to the Alzheimer’s Association. Read more...
October 16, 2014 4:22 pm
Cynthia Fox, Science Editor
Two historic drugs for idiopathic pulmonary fibrosis (IPF) received “fast track, priority review, orphan product, and breakthrough designation” approval Wednesday from the Food and Drug Administration (FDA). Read more...
October 13, 2014 4:50 pm
Dragan Cicic, M.D., MBA, Chief Operating Officer and Chief Medical Officer, Actinium Pharmaceuticals
For patients with acute myeloid leukemia (AML), there is both good news and bad news – the good news is that standard induction therapy, using cytarabine and an anthracycline, produces complete responses in half to almost three-quarters of cases. The bad news? Read more...
October 10, 2014 8:30 am
Merrilyn Datta, Ph.D., Chief Commercial Officer, Definiens
Just four years after the drug sipuleucel-T was approved for clinical adoption, the field of immunotherapy is on the cusp of a number of exciting advancements. Read more...                           
October 7, 2014 8:30 am
Nuno Goncalves, Manager of Novel Biomolecular Detection, EMD Millipore
Protein detection and quantitation is required daily in thousands of laboratories worldwide for activities ranging from protein characterization to clinical diagnostic testing to drug dosing. Read more...                
October 3, 2014 11:04 am
Stephanie Guzowski, Editor
As the deadly Ebola outbreak in West Africa continues to grip headlines around the world, researchers move steadily forward with drug development. But as essential as it is to contain the current Ebola outbreak, researchers are looking at the bigger picture— and highlighting the need for therapy development to extend beyond the wake of the current epidemic. Read more...
Subscribe to Drug Discovery & Development